Global Chronic Obstructive Pulmonary Disease (COPD) Market Introduction and Overview
According to SPER Market Research, the Global Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to reach USD 33.31 billion by 2033 with a CAGR of 4.68%.
The report includes an in-depth analysis of the Global Chronic Obstructive Pulmonary Disease (COPD) Market, including market size and trends, product mix, applications, and supplier analysis. The chronic inflammatory lung illness known as chronic obstructive pulmonary disease (COPD) makes it difficult for air to leave the lungs. Coughing, wheezing, mucus production, and trouble breathing are some of the symptoms of COPD. Chronic obstructive pulmonary disease is a group of lung illnesses that can cause breathing difficulties. Emphysema and chronic bronchitis are the two primary types of chronic obstructive pulmonary diseases. Breathing problems are one of the primary indicators of COPD. The rise in COPD cases in populations around the world is one important factor that is expected to hasten the growth and consumer demand of the chronic obstructive pulmonary disease sector.
- Trelegy Ellipta was introduced by GlaxoSmithKline Pharmaceuticals in April 2022 for patients with Chronic Obstructive Pulmonary Disease (COPD). For patients with COPD, Trelegy Ellipta is the first once-daily single-inhaler triple treatment (SITT) available in India.
- Teva announced in February 2022 that the FDA has approved ArmonAir Digihaler inhalation powder, an inhaled corticosteroid (ICS) that is administered through Teva's DigihalerTM device, which has sensors embedded in and connects to a companion mobile application that gives asthmatics information on how to utilize their inhalers.
Market Opportunities and Challenges
Opportunities- The increasing prevalence of chronic obstructive pulmonary disease (COPD) is underscored by a 2019 study from the National Center for Biotechnology Information, which reported 212.3 million cases worldwide. This condition accounted for 3.3 million deaths and resulted in 74.4 million disability-adjusted life years (DALYs). Additionally, the American Lung Association highlighted that in 2018, 9.0 million adults (3.6% of those aged 18 and older) were affected by chronic bronchitis. Furthermore, 16.4 million adults (6.6%) reported being diagnosed with some form of COPD, including chronic bronchitis and emphysema. As the incidence of COPD continues to rise, significant market growth in treatments and interventions is anticipated in the near future.
Furthermore, the majority of COPD treatments concentrate on controlling symptoms and delaying the illness's progression. Nonetheless, there is a great need for novel and creative treatments that enhance patients' quality of life and yield better results. New COPD treatments, such as gene therapies, biologics, and other cutting-edge methods, have been the focus of research and development in recent years. These medicines possibly address the fundamental causes of COPD and give patients with more effective and focused therapy alternatives.
Challenges-
Expensive treatment: As a chronic illness, COPD frequently necessitates costly, long-term care and specialized treatment. Furthermore, a large number of COPD patients also have other comorbidities, which raises the expense of healthcare even more. Many patients find that the expense of treating COPD is a significant barrier to access, especially in poor nations where insurance coverage is limited and healthcare expenditures are high. This has a detrimental effect on patient outcomes and quality of life since it results in underdiagnosis and undertreatment of the illness.
Market Competitive Landscape
The Global Chronic Obstructive Pulmonary Disease (COPD) Market is highly consolidated. Some of the market key players are Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Treatment Type, By End User |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others. |
COVID-19 Impact on Global Chronic Obstructive Pulmonary Disease (COPD) Market
The global market for chronic obstructive pulmonary disease (COPD) has been greatly impacted by the COVID-19 epidemic, presenting both potential and challenges. Because of their underlying respiratory disorders, people with COPD were at higher risk during the pandemic, which led to more hospitalizations and a greater emphasis on respiratory health. Prioritizing COVID-19 reactions caused healthcare systems to frequently disrupt routine COPD care and management, which impacted patients' access to medications and made their diseases worse.
Key Target Audience:
- Patients with Chronic Obstructive Pulmonary Disease (COPD)
- Healthcare Providers
- Pharmaceutical Companies
- Medical Device Manufacturers
- Researchers and Academia
- Health Insurance Providers
- Government and Regulatory Agencies
Our in-depth analysis of the Global Chronic Obstructive Pulmonary Disease (COPD) Market includes the following segments:
| By Type: | Chronic BronchitisEmphysema |
| By Treatment Type: | DrugsBronchodilator MonotherapyShort-Acting Beta2-Agonists (SABAS)Long-Acting Beta2-Agonists (LABAS)Anti-Cholinergic AgentsAnti-Inflammatory DrugsOral And Inhaled CorticosteroidsAnti-LeukotrienesSurgeryLung Volume Reduction Surgery (LVRS)Lung Transplant, Bullectomy Others |
| By End User: | HospitalsHomecare SettingsClinicsOthers |
Key Topics Covered in the Report:
- Global Chronic Obstructive Pulmonary Disease (COPD) Market Size (FY’2024-FY’2033)
- Overview of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Segmentation of Global Chronic Obstructive Pulmonary Disease (COPD) Market By Type (Chronic Bronchitis, Emphysema)
- Segmentation of Global Chronic Obstructive Pulmonary Disease (COPD) Market By Treatment Type (Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others)
- Segmentation of Global Chronic Obstructive Pulmonary Disease (COPD) Market By End User (Hospitals, Homecare Settings, Clinics, Others)
- Statistical Snap of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Expansion Analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Problems and Obstacles in Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Competitive Landscape in the Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Impact of COVID-19 and Demonetization on Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Details on Current Investment in Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Competitive Analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Prominent Players in the Global Chronic Obstructive Pulmonary Disease (COPD) Market
- SWOT Analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Global Chronic Obstructive Pulmonary Disease (COPD) Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Chronic Obstructive Pulmonary Disease (COPD) Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chronic Obstructive Pulmonary Disease (COPD) Market
7. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Type (USD Million) 2020-2033
7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2020-2026
7.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2027-2033
7.3. Chronic Bronchitis
7.4. Emphysema
8. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Treatment Type (USD Million) 2020-2033
8.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2020-2026
8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2027-2033
8.3. Drugs
8.4. Bronchodilator Monotherapy
8.5. Short-Acting Beta2-Agonists (SABAS)
8.6. Long-Acting Beta2-Agonists (LABAS)
8.7. Anti-Cholinergic Agents
8.8. Anti-Inflammatory Drugs
8.9. Oral And Inhaled Corticosteroids
8.10. Anti-Leukotrienes
8.11. Surgery
8.12. Lung Volume Reduction Surgery (LVRS)
8.13. Lung Transplant, Bullectomy
8.14. Others
9. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By End User (USD Million) 2020-2033
9.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Homecare Settings
9.5. Clinics
9.6. Others
10. Global Chronic Obstructive Pulmonary Disease (COPD) Market Forecast, 2020-2033 (USD Million)
10.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share
11. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2020-2033 (USD Million)
11.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2020-2026)
11.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Pfizer Inc
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Merck & Co., Inc
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Novartis AG
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. AstraZeneca
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. GlaxoSmithKline plc
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Roche (F. Hoffmann-La Roche Ltd, Switzerland)
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Abbott
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Boehringer Ingelheim International GmbH
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Biogen
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links